MYGN
NASDAQ · Biotechnology
Myriad Genetics Inc
$3.25
+0.07 (+2.20%)
Open$3.23
Previous Close$3.18
Day High$3.29
Day Low$3.19
52W High$8.59
52W Low$2.74
Volume—
Avg Volume3.96M
Market Cap311.82M
P/E Ratio—
EPS$-1.20
SectorBiotechnology
Analyst Ratings
Sell
15 analysts
Price Target
+1,175.1% upside
Current
$3.25
$3.25
Target
$41.44
$41.44
$29.39
$41.44 avg
$63.29
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 854.28M | 800.48M | 74.53M |
| Net Income | -379,112,963 | -319,716,704 | -15,758,896 |
| Profit Margin | -44.4% | -42.2% | -21.1% |
| EBITDA | -345,542,171 | -307,594,698 | -16,042,014 |
| Free Cash Flow | — | — | -13,316,178 |
| Rev Growth | +6.7% | +6.7% | +5.3% |
| Debt/Equity | 0.33 | 0.33 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |